Cargando…

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia

Detalles Bibliográficos
Autores principales:	ALMAGRO, D, AGRAMONTE, O, CASTILLO, D, ZAMORA, Y, BALLESTER, J M
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Letters to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083519/ https://www.ncbi.nlm.nih.gov/pubmed/21332884 http://dx.doi.org/10.1111/j.1365-2516.2010.02403.x

Ejemplares similares

Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding
por: Chang, Zhi-gang, et al.
Publicado: (2020)

Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding
por: Habib, Aly Makram
Publicado: (2016)

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries
por: Bensadok, Meriem, et al.
Publicado: (2017)

Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
por: Klitgaard, Thomas, et al.
Publicado: (2006)

Activated recombinant factor VII in management of bleeding in patients with thrombocytopenia
por: Shulutko, E, et al.
Publicado: (2006)

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
por: Habib, Aly Makram, et al.
Publicado: (2016)

Use of recombinant activated factor VII for bleeding following resection of mediastinal angiosarcoma
por: Arora, D, et al.
Publicado: (2011)

Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients
por: AlGahtani, Farjah H., et al.
Publicado: (2010)

Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis
por: Abuhasna, Said D., et al.
Publicado: (2012)

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
por: Johansson, Pär I, et al.
Publicado: (2010)

Recombinant activated factor VII for the treatment of bleeding in abdominal surgery and cardiac surgery
por: Michalska, G, et al.
Publicado: (2009)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Recombinant activated factor VII in cardiac surgery – first, do no harm
por: Warren, Oliver J, et al.
Publicado: (2007)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial
por: Lentz, Steven R., et al.
Publicado: (2017)

Recombinant proteins in therapeutics: haemophilia treatment as an example
por: Liras, Antonio
Publicado: (2008)

Recombinant activated factor VII treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, and efficacy and safety outcomes
por: Liebl, M, et al.
Publicado: (2007)

Thrombomodulin in patients with mild to moderate bleeding tendency
por: Mehic, Dino, et al.
Publicado: (2021)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery
por: Barua, Anupama, et al.
Publicado: (2011)

Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation
por: Hollis, Allison L., et al.
Publicado: (2016)

The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
por: Altman, Raul, et al.
Publicado: (2010)

Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases
por: Saito, Makoto, et al.
Publicado: (2016)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
por: Golestani, Mina, et al.
Publicado: (2014)

Haemophilia A associated with Down’s syndrome
por: Kaczorowska-Hac, Barbara, et al.
Publicado: (2012)

Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience
por: Han, Myung Hee, et al.
Publicado: (2013)

Two years experience with low-dose recombined activated factor VII treatment of non-haemophilic patients
por: Michalska, G, et al.
Publicado: (2006)

Burden of mild haemophilia A: Systematic literature review
por: Peyvandi, Flora, et al.
Publicado: (2019)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia
por: Broderick, Carolyn R, et al.
Publicado: (2008)

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
por: Vincent, Jean-Louis, et al.
Publicado: (2006)

Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy †
por: Laxar, Daniel, et al.
Publicado: (2023)

Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment
por: Benton, Melody, et al.
Publicado: (2020)

Systemic Therapy In Acquired Haemophilia – A Single Institute Experience
por: Sarah, Lawless, et al.
Publicado: (2016)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply
por: De Monte, Amato, et al.
Publicado: (2021)

Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency
por: Seanoon, Karnsasin, et al.
Publicado: (2022)

Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea
por: Baek, Hee Jo, et al.
Publicado: (2020)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_b8duq8ico8dfps855rvtkon00p